Abstract:Background & Aim Acute respiratory distress syndrome (ARDS) is a severe hypoxemic respiratory failure characterized by recognizable diffuse alveolar damage and lung injury, with high mortality. Unfortunately, the current treatment for ARDS is mainly supportive. Although preclinical models of ARDS have demonstrated that mesenchymal stromal cells (MSCs) protects the lung against injury, their mechanisms are not yet fully understood. Accumulating evidence has indicated that the cholinergic anti-inflammatory pathway (CAP) is involved in controlling inflammation in various inflammatory situations, we then investigate whether CAP play the critical role in the therapeutic effect of MSC to mitigate ARDS. Methods, Results & Conclusion Lipopolysaccharide (LPS)-induced lung injury model was induced in C57BL/6J mice by nasal drip, followed by an intravenous injection of MSCs or saline 6 hours later. Lung tissue was profiled in three groups of MSC or saline treatment in lung-injury mice and sham in wild type mice. AR-R1779HCl and Methyllycaconitine citrate were used to specifically activate or block α7nAChR respectively. Indomethacin and MF63, inhibiting PTGES and PGES-1 respectively, were used to restrain MSC producing PGE2. After MSC infusions to LPS-induce lung injury mice, the pulmonary vascular permeability were improved and inflammatory cell infiltration were reduced within 6 hours. The expression profile sequencing of lung tissue showed that ChAT, VAChT and other cholinergic system-related genes were significantly increased after MSC treatment. When specifically blocking the acetylcholine (ACh) receptor 7nAChR, the therapeutic effects of MSC significantly reduced, suggesting that the cholinergic anti-inflammatory pathway (CAP) may play an important role in MSC treating ARDS. Moreover, prostaglandin E2 (PGE2) produced by MSC, likely to increase ChAT synthesis of cholinergic nerves. These results supported that MSCs inhibit severe inflammatory response of ARDS through activating CAP-mediated anti-inflammatory regulation, partially through increasing the synthesis of acetylcholine via PGE2. In summary, we have revealed a previously unrecognized mechanism of MSC-mediated activation of the cholinergic anti-inflammatory pathway in alleviating ARDS-like syndrome, which provide evidences for clinical translation of MSC in patients with ARDS. Acute respiratory distress syndrome (ARDS) is a severe hypoxemic respiratory failure characterized by recognizable diffuse alveolar damage and lung injury, with high mortality. Unfortunately, the current treatment for ARDS is mainly supportive. Although preclinical models of ARDS have demonstrated that mesenchymal stromal cells (MSCs) protects the lung against injury, their mechanisms are not yet fully understood. Accumulating evidence has indicated that the cholinergic anti-inflammatory pathway (CAP) is involved in controlling inflammation in various inflammatory situations, we then investigate whether CAP play the critical role in the therapeutic effect of MSC to mitigate ARDS. Lipopolysaccharide (LPS)-induced lung injury model was induced in C57BL/6J mice by nasal drip, followed by an intravenous injection of MSCs or saline 6 hours later. Lung tissue was profiled in three groups of MSC or saline treatment in lung-injury mice and sham in wild type mice. AR-R1779HCl and Methyllycaconitine citrate were used to specifically activate or block α7nAChR respectively. Indomethacin and MF63, inhibiting PTGES and PGES-1 respectively, were used to restrain MSC producing PGE2.

Abstract PR566

Mesenchymal Stem Cell-Educated Macrophages Ameliorate Lps-Induced Systemic Response

Mesenchymal Stem Cells Alleviate LPS-induced Acute Lung Injury by Inhibiting the Proinflammatory Function of Ly6C+ CD8+ T Cells

Adipose-Derived Mesenchymal Stem Cells Ameliorating Pseudomonas aeruginosa–induced Acute Lung Infection via Inhibition of NLRC4 Inflammasome

Treatment of Acute Respiratory Distress Syndrome with Allogeneic Adipose-Derived Mesenchymal Stem Cells: a Randomized, Placebo-Controlled Pilot Study.

Human Umbilical Cord Mesenchymal Stem Cells Promote Macrophage PD-L1 Expression and Attenuate Acute Lung Injury in Mice

Adipose-Derived Mesenchymal Stem Cells Ameliorating <i>Pseudomonas aeruginosa</i>-induced Acute Lung Infection <i>via</i> Inhibition of NLRC4 Inflammasome

Placental mesenchymal stem cells boost M2 alveolar over M1 bone marrow macrophages via IL-1β in Klebsiella-mediated acute respiratory distress syndrome

Differential Effects of Extracellular Vesicles from Aging and Young Mesenchymal Stem Cells in Acute Lung Injury

Mesenchymal Stem Cell–Derived Extracellular Vesicles Alleviate Acute Lung Injury Via Transfer of Mir-27A-3p*

Immunosuppressive Effect Of Mesenchymal Stem Cells On Lung And Gut Cd8(+) T Cells In Lipopolysaccharide-Induced Acute Lung Injury In Mice

Studies on the Effects of Bone Marrow Stem Cells on Mitochondrial Function and the Alleviation of ARDS

Bone Marrow Mesenchymal Stem Cell-Derived Exosomes Attenuate LPS-Induced ARDS by Modulating Macrophage Polarization Through Inhibiting Glycolysis in Macrophages.

Placental mesenchymal stem cells suppress inflammation and promote M2-like macrophage polarization through the IL-10/STAT3/NLRP3 axis in acute lung injury

Mesenchymal stem cell-mediated immunomodulation of recruited mononuclear phagocytes during acute lung injury: a high-dimensional analysis study

MSCs alleviate LPS-induced acute lung injury by inhibiting the proinflammatory function of macrophages in mouse lung organoid–macrophage model

Advances in the Regulation of Macrophage Polarization by Mesenchymal Stem Cells and Implications for ALI/ARDS Treatment

Adrenaline Stimulated Mesenchymal Stem Cells Modulate Inflammation in Lipopolysaccharide Induced Lung Injury

Mesenchymal Stromal Cells Alleviates Experimental Acute Respiratory Distress Syndrome Through the Cholinergic Anti-Inflammatory Pathway

Mesenchymal Stem Cells Attenuate Acute Lung Injury in Mice Partly by Suppressing Alveolar Macrophage Activation in a PGE2-dependent Manner